EDElizabeth A. Douglas

Elizabeth A. Douglas

*This is an algorithmically generated author record based on publicly available information.

Elizabeth A. Douglas has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Ailsa Power

    NHS Education for Scotland, Glasgow, UK

    1 shared publication
  • Andrew Bouley

    The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA, USA

    1 shared publication
  • Cheongeun Oh

    Department of Population Health, New York University Langone Health, New York, NY, USA

    1 shared publication
  • Ellen Lathi

    NYU Multiple Sclerosis Comprehensive Care Center (IK, TEB), Department of Neurology; Department of Population Health (CO), NYU Grossman School of Medicine, New York; The Elliot Lewis Center for Multiple Sclerosis Care (EAD, ILOS, AB, EL, JK), Wellesley, MA; and St. Peter's MS and Headache Center (EHP), Albany, NY

    1 shared publication
  • Ellen Lathi

    NYU Multiple Sclerosis Comprehensive Care Center (IK, TEB), Department of Neurology; Department of Population Health (CO), NYU Grossman School of Medicine, New York; The Elliot Lewis Center for Multiple Sclerosis Care (EAD, ILOS, AB, EL, JK), Wellesley, MA; and St. Peter's MS and Headache Center (EHP), Albany, NY

    1 shared publication
  • Erica H. Parrotta

    NYU Multiple Sclerosis Comprehensive Care Center (IK, TEB), Department of Neurology; Department of Population Health (CO), NYU Grossman School of Medicine, New York; The Elliot Lewis Center for Multiple Sclerosis Care (EAD, ILOS, AB, EL, JK), Wellesley, MA; and St. Peter's MS and Headache Center (EHP), Albany, NY

    1 shared publication

Latest Publications

  • Open Access

    No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis

    by Ilya Kister, Cheongeun Oh, Elizabeth A. Douglas, Tamar E. Bacon, Isabella L. O'SHea, Erica H. Parrotta, Andrew Bouley, Ellen Lathi, Joshua Katz

    Background and Objectives Some patients with multiple sclerosis (MS) receiving ocrelizumab (OCR) report worsening symptoms toward the end of the 6-month infusion cycle (‘wearing off’). The objective of our study was to comprehensively assess changes in symptom burden across 2 consecutive OCR infusion cycles. Methods SYMptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS; NCT04855617) was an investigator-initiated, 2-center study of patients with MS starting or receiving OCR. Patients9 symptoms were assessed with NeuroQoL short forms, SymptoMScreen, and Work Productivity and Activity Impairment Questionnaire at the start-cycle, mid-cycle, and end-cycle time points in each of the 2 infusion cycles. Symptom scores at the 3 time points within each cycle were compared with repeated-measures ANOVA or the Friedman rank-sum test for non-normal variables. The proportions of patients with a meaningful symptomatic change from the start to the end of each infusion cycle were calculated, and patients whose symptoms improved, worsened, and stayed the same from the start to the end of the cycle were compared with respect to demographic and clinical characteristics. Results One hundred three patients with MS provided longitudinal data for analyses (mean age [SD]: 46.7 [12.2] years, 68% female, 33% non-White, disease duration: 15.5 [5] years, 41% with the Extended Disability Status Scale score >3). On a group level, NeuroQoL and SymptoMScreen scores mostly remained stable or even improved slightly toward the end of each cycle. On an individual level, symptoms remained unchanged across either cycle for most patients, and meaningful symptom worsening from the start to the end of the cycle was no more common than improvement. Meaningful change in symptoms in both cycles was very rare and generally in the direction of improvement toward the end cycle. Despite the lack of evidence for symptom worsening with a longer time from infusion, 54% of patients endorsed feeling of “wearing off” at least sometimes, most commonly as an increase in fatigue. Discussion Our prospective study failed to uncover evidence for the worsening of symptoms with a longer time from OCR infusion. These findings cast doubt on the existence of wearing off as a physiologic phenomenon in OCR-treated patients with MS. The perception of wearing off is likely the result of natural fluctuations in MS symptoms and attribution bias.


  • Open Access

    Pharmaceutical care of the patient with diabetes mellitus: pharmacists' priorities for services and educational needs in Scotland

    by Elizabeth Douglas, Ailsa Power, Steve Hudson

    Objective To determine the extent of service provision by pharmacists in Scotland to patients with diabetes. Also, to investigate pharmacists' perceived education needs and their priorities for future service development to this patient group. Setting A random sample of pharmacists in Scotland who had previously participated in NHS Education for Scotland (NES) education. Method Questionnaire survey of pharmacists to estimate extent of provision of 28 defined aspects of diabetes care, educational needs and their professional aspirations. Key findings Approximately two‐thirds of community pharmacists who responded offered the following patient‐centred services for patients with diabetes and included education/advice on: lifestyle, smoking cessation, medicines administration times, footcare and self‐monitoring of glycaemia. Perceived need for further education was found to be linked with levels of service provision. Priorities for development of future services in this patient group were established, and preferred methods of educational support were also examined. Conclusion Pharmacists in Scotland are providing services for patients with diabetes although these are not consistent. The profession in Scotland also has clear ideas of future priorities in practice for this patient group. However there is a need to provide further training and education in order to support service development.